Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review-Reference-Cited by-同舟云学术

Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review

Published:2015-08 Issue:8 Volume:10 Page:1148-1155
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Créquit Perrine,Wislez Marie,Fleury Feith Jocelyne,Rozensztajn Nathalie,Jabot Laurence,Friard Sylvie,Lavole Armelle,Gounant Valérie,Fillon Julie,Antoine Martine,Cadranel Jacques

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference34 articles.

1. Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts);Barlesi;J Clin Oncol,2013

2. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N Engl J Med,2010

3. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005;Crinò;J Clin Oncol,2011

4. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2013

5. PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N Engl J Med,2014

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lung cancer, comorbidities, and medication: the infernal trio;Frontiers in Pharmacology;2024-02-21

2. Determining Risks and Treating of Radiation Pneumonitis After Thoracic Radiation;Complications of Cancer Therapy: Best Practices in Prevention and Management;2024

3. Lung Injury Induced by Crizotinib and Entrectinib in a Patient with <i>ROS1</i>-rearranged Non-small-cell Lung Cancer;Internal Medicine;2023-12-01

4. Lorlatinib following alectinib-induced pneumonitis: A case report;JTO Clinical and Research Reports;2023-10

5. A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease;Journal of Zhejiang University (Medical Sciences);2023-10-01